Introduction: The TNM staging system proposed by the AJCC exclusively considers anatomical factors of the tumor, classifying tumors with similar clinical outcomes while disregarding factors intrinsic to tumor biology. The Stage III tumors are locally advanced breast carcinoma and a big challenge due to their high recurrence rate. However, patients in this stage with favorable biological tumor markers have a better prognosis. In 2018, the AJCC proposed Prognostic Staging, incorporating the Nottingham grade and prognostic and predictive factors such as estrogen receptor, progesterone receptor, and HER-2 oncogene expression into the anatomical TNM solving its limitations. Objectives: This study aimed to evaluate the prognostic staging of locally advanced sporadic breast carcinoma in patients treated at a university hospital in the state of Pará. Methods: A retrospective descriptive analytical study with both qualitative and quantitative approaches was conducted. Breast carcinomas staged as groups IIIA, IIIB, and IIIC in women treated for breast cancer at a university hospital between 2019 and 2024 were re-evaluated. Data were obtained from medical records, histopathology, and immunohistochemistry reports and entered into the secure platform RedCap using variable instrumentation. The information required for prognostic staging was entered into the "TNM Cancer Staging Calculator" (Integrated Cancer Research, 2023) grouping them according to the prognostic TNM. The association between the change in staging and the molecular type was determined by creating a contingency table, which was subjected to the chi-square test (p<0.05). The study was approved by the Research Ethics Committee under CAAE 55998522.1.0000.5634. Results: From a cohort of 306 patients with complete clinical records, 30 were diagnosed with locally advanced breast carcinoma. This group had a mean age of 53.6 years. The predominant histological type was invasive carcinoma of no special type (NST), comprising 76.7% of the cases. The most prevalent molecular subtype was Luminal A, representing 30% of the sample, followed by Luminal B HER-2 negative (27.3%), Triple Negative (20%), HER-2 positive (16.7%), and Luminal B HER-2 positive (10%). Regarding anatomical staging, 50% were classified as stage IIIA, 20% as IIIB, and 30% as IIIC. In terms of prognostic staging, patients were distributed as follows: 26.7% in stage IB, 3.3% in IIA, 10% in IIB, 30% in IIIA, 13.3% in IIIB, and 16.7% in IIIC. When comparing the groupings, 76.7% of the patients experienced a change in staging, with 70% being downstaged and 6.7% upstaged. The association between molecular subtype with re-staging has stastistical significance (P<0.05), it was observed that 85.7% of the downstaged cases occurred in those classified as luminal, while all the upstaged cases occurred in triple-negative breast carcinoma. Conclusion: The change in stage with prognostic staging in 76.7% of cases demonstrates the importance of this methodology. Since different stages do not have similar prognoses, this allows for precise clinical decision-making. The association between molecular subtype and re-staging shows the impact of biomarkers on the prognosis of patients with locally advanced tumors. This underscores the significance of prognostic staging in this patient case series with invasive breast carcinoma treated at a northern Brazil public hospital.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
